Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
HIV protease inhibitor |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:J05AE03
|
| gptkbp:boostsEffectOf |
other protease inhibitors
|
| gptkbp:brand |
gptkb:Ritonavir
|
| gptkbp:CASNumber |
gptkb:155213-67-5
|
| gptkbp:component |
antiretroviral therapy
|
| gptkbp:developedBy |
gptkb:Abbott_Laboratories
|
| gptkbp:discoveredIn |
1990s
|
| gptkbp:hasMolecularFormula |
C37H48N6O5S2
|
| https://www.w3.org/2000/01/rdf-schema#label |
ABT-538
|
| gptkbp:mechanismOfAction |
inhibits HIV-1 and HIV-2 protease
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea lipodystrophy hyperlipidemia |
| gptkbp:synonym |
gptkb:Norvir
|
| gptkbp:usedFor |
HIV/AIDS treatment
|
| gptkbp:bfsParent |
gptkb:Norvir
|
| gptkbp:bfsLayer |
7
|